1217675-13-2
Chemical Structure
Lubiprostone-d7
Synonym(s): RU-0211-d7;SPI-0211-d7
- CAS 番号: 1217675-13-2
- Formula:C20H25D7F2O5
- Molecular Weight:397.51
IUPAC Name: 7-((1R,2R,3R)-2-(4,4-difluoro-3-oxooctyl-6,6,7,7,8,8,8-d7)-3-hydroxy-5-oxocyclopentyl)heptanoic acid
InChIKey: DBVFKLAGQHYVGQ-QHZIEZROSA-N
SMILES: C(CC(C(CC(C(C([2H])([2H])[2H])([2H])[2H])([2H])[2H])(F)F)=O)[C@@H]1[C@@H](CCCCCCC(O)=O)C(=O)C[C@H]1O
Biological Activity: Lubiprostone-d7 (RU-0211-d7) is the deuterium labeled Lubiprostone. Lubiprostone (SPI-0211) increases intestinal fluid secretion through generation of CIC-2/CFTR and activation of cAMP signaling pathway. Lubiprostone inhibits myeloperoxidase (MPO) activity, downregulates Indomethacin (HY-14397)-induced iNOS and TNFα expression. Lubiprostone can be used for chronic constipation research[1][2][3].
| 製品番号 | 製品名 | 純度 | 製品説明 | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Lubiprostone-d7 | Lubiprostone-d7 (RU-0211-d7) is the deuterium labeled Lubiprostone. Lubiprostone (SPI-0211) increases intestinal fluid secretion through generation of CIC-2/CFTR and activation of cAMP signaling pathway. Lubiprostone inhibits myeloperoxidase (MPO) activity, downregulates Indomethacin (HY-14397)-induced iNOS and TNFα expression. Lubiprostone can be used for chronic constipation research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lubiprostone (Standard) | ≥98% | Lubiprostone (Standard) is the analytical standard of Lubiprostone. This product is intended for research and analytical applications. Lubiprostone (SPI-0211) increases intestinal fluid secretion through generation of CIC-2/CFTR and activation of cAMP signaling pathway. Lubiprostone inhibits myeloperoxidase (MPO) activity, downregulates Indomethacin (HY-14397)-induced iNOS and TNFα expression. Lubiprostone can be used for chronic constipation research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lubiprostone | 99.09% | Lubiprostone (SPI-0211) increases intestinal fluid secretion through generation of CIC-2/CFTR and activation of cAMP signaling pathway. Lubiprostone inhibits myeloperoxidase (MPO) activity, downregulates Indomethacin (HY-14397)-induced iNOS and TNFα expression. Lubiprostone can be used for chronic constipation research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
